Investors seeking a more defensive positioning have rushed into health care stocks in recent months, as hype about the aging…
McAlinden Research PartnersFebruary 4, 2019
“CRISPR babies” have been on everyone’s lips since news broke last week that Chinese scientists claimed they had produced the…
McAlinden Research PartnersDecember 4, 2018
The Trump Administration may finally be taking serious action against the pharmaceutical industry in a bid to cut down heavily…
McAlinden Research PartnersOctober 30, 2018
CRISPR stocks have gotten battered in the second half of the year, yet the precision gene-editing technology is proving to…
McAlinden Research PartnersOctober 25, 2018
The administration has, thus far, taken measured action against drug prices since President Trump announced his “blueprint” to tackle high…
McAlinden Research PartnersAugust 15, 2018
While the US meat industry has lately been racked by trade war fallout, resulting in huge surpluses, domestic demand is…
McAlinden Research PartnersAugust 9, 2018
Short U.S. Health Care Providers has been on MRP’s list of themes since October 16, 2017, and we’ve been monitoring…
McAlinden Research PartnersJune 27, 2018
Faced with growing demand for improved delivery of health services at lower costs, the U.S. health care industry is transitioning…
McAlinden Research PartnersJune 25, 2018
Market reaction to a report that cells edited with CRISPR technology can activate a cancer-causing gene has been severe for…
McAlinden Research PartnersJune 13, 2018
